Your browser doesn't support javascript.
loading
METTL3-m6A-EGFR-axis drives lenvatinib resistance in hepatocellular carcinoma.
Wang, Lina; Yang, Qingxia; Zhou, Qianying; Fang, Fei; Lei, Kai; Liu, Ziqin; Zheng, Gaomin; Zhu, Lefan; Huo, Jihui; Li, Xiaoxing; Peng, Sui; Kuang, Ming; Lin, Shuibin; Huang, Manling; Xu, Lixia.
Afiliação
  • Wang L; Institute of Precision Medicine, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
  • Yang Q; Institute of Precision Medicine, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China; Department of Oncology, Cancer Center, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
  • Zhou Q; Institute of Precision Medicine, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China; Department of Oncology, Cancer Center, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
  • Fang F; Clinical Trial Unit, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
  • Lei K; Institute of Precision Medicine, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China; Center of Gastrointestinal Surgery, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
  • Liu Z; Institute of Precision Medicine, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China; Department of Oncology, Cancer Center, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
  • Zheng G; Institute of Precision Medicine, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China; Department of Oncology, Cancer Center, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
  • Zhu L; Institute of Precision Medicine, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
  • Huo J; Department of Oncology, Cancer Center, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
  • Li X; Institute of Precision Medicine, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
  • Peng S; Institute of Precision Medicine, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China; Clinical Trial Unit, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China; Department of Gastroenterology and Hepatology, The First Affiliated Hospital, Sun Yat-sen University
  • Kuang M; Institute of Precision Medicine, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China; Center of Hepato-Pancreato-Biliary Surgery, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
  • Lin S; Institute of Precision Medicine, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China; Center for Translational Medicine, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China. Electronic address: linshb6@mail.sysu.edu.cn.
  • Huang M; Institute of Precision Medicine, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China; Department of Oncology, Cancer Center, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China. Electronic address: huangmling7@mail.sysu.edu.cn.
  • Xu L; Institute of Precision Medicine, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China; Department of Oncology, Cancer Center, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China. Electronic address: xulixia@mail.sysu.edu.cn.
Cancer Lett ; 559: 216122, 2023 04 10.
Article em En | MEDLINE | ID: mdl-36898427
ABSTRACT
Lenvatinib is emerging as the first-line therapeutic option for advanced hepatocellular carcinoma (HCC), but drug resistance remains a major hurdle for its long-term therapy efficiency in clinic. N6-methyladenosine (m6A) is the most abundant mRNA modification. Here, we aimed to investigate the modulatory effects and underlying mechanisms of m6A in lenvatinib resistance in HCC. Our data revealed that m6A mRNA modification was significantly upregulated in the HCC lenvatinib resistance (HCC-LR) cells compared to parental cells. Methyltransferase-like 3 (METTL3) was the most significantly upregulated protein among the m6A regulators. Either genetic or pharmacological inhibition of m6A methylation through METTL3 deactivation in primary resistant cell line MHCC97H and acquired resistant Huh7-LR cells decreased cell proliferation and increased cell apoptosis upon lenvatinib treatment in vitro and in vivo. In addition, the specific METTL3 inhibitor STM2457 improved tumor response to lenvatinib in multiple mouse HCC models, including subcutaneous, orthotopic and hydrodynamic models. The MeRIP-seq results showed that epidermal growth factor receptor (EGFR) was a downstream target of METTL3. EGFR overexpression abrogated the METTL3 knocked down-induced cell growth arrest upon lenvatinib treatment in HCC-LR cells. Thus, we concluded that targeting METTL3 using specific inhibitor STM2457 improved the sensitivity to lenvatinib in vitro and in vivo, indicating that METTL3 may be a potential therapeutic target to overcome lenvatinib resistance in HCC.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Carcinoma Hepatocelular / Resistencia a Medicamentos Antineoplásicos / Neoplasias Hepáticas Tipo de estudo: Prognostic_studies Limite: Animals / Humans Idioma: En Revista: Cancer Lett Ano de publicação: 2023 Tipo de documento: Article País de afiliação: China

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Carcinoma Hepatocelular / Resistencia a Medicamentos Antineoplásicos / Neoplasias Hepáticas Tipo de estudo: Prognostic_studies Limite: Animals / Humans Idioma: En Revista: Cancer Lett Ano de publicação: 2023 Tipo de documento: Article País de afiliação: China